In previous work, we showed that FOXD1 expression correlates with poor patient outcomes in ccRCC, that its inactivation in ccRCC cells delays progression through the G2/M phase of the cell cycle, and that FOXD1 loss prevents tumor growth in a xenograft model [8]. The gene discussed is FOXD1; the disease is nonpapillary renal cell carcinoma.